Bagsværd, Denmark, 12 June 2023 - Novo Nordisk today announced plans to invest 15.9 billion Danish kroner starting in 20231 to expand an existing Active Pharmaceutical Ingredient (API) production facility in Denmark for the future portfolio within serious chronic diseases.
PharmiWeb Recruiter Blog
Bristol Myers Squibb Receives U.S. FDA Approval of New State-of-the-Art Cell Therapy Manufacturing Facility in Devens, Massachusetts
The company’s third commercial CAR T manufacturing facility in the U.S. further extends Bristol Myers Squibb’s leadership in cell therapy
In the competitive landscape of life science recruitment, a well-optimised careers page on your company’s website can make all the difference when it comes to presenting your organisation as an employer of choice and attracting top talent.
- Wednesday 21st June 2023
- 16:00 BST - 11:00 EST - 08:00 PST
- Free to Join
Are you looking to improve your organisation’s Diversity, Equity, and Inclusion strategy? Do you want to learn best practices from one of the world’s leading clinical research organisations?
In an era characterised by rapid advancements in science and technology, the influence of younger generations cannot be overlooked. As life science recruiters, it’s crucial to understand and address the top societal concerns of Gen Z and millennial jobseekers in order to attract and retain top talent in 2023 and beyond.
Advanced Clinical and StuffThatWorks Join Forces to Bring Patients and Caregivers Closer to Clinical Trials
Chicago, IL (May 25, 2023) — Advanced Clinical, a privately held clinical research services organization committed to providing a better clinical experience across the drug development journey, is pleased to announce a biopharmaceutical industry-first collaboration with StuffThatWorks, the first data-driven community platform that uses crowdsourcing and AI to transform patient journeys and health metrics into actionable real world data in an effort to streamline research and bring clinical research closer to patients and caregivers.
Parexel Rated “Top CRO to Work With” in 2023 WCG CenterWatch Global Site Relationship Benchmark Survey for Second Straight Time
Company receives highest average rating across all 26 performance attributes out of 34 CROs included in survey and highest Net Promoter Score demonstrating likelihood to be recommended to colleagues
DURHAM, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced it has been rated the “Top CRO to Work With” by investigative sites worldwide in the 2023 WCG CenterWatch Global Site Relationship Benchmark Survey. Among the 34 CROs included in the survey, Parexel received the highest average rating across all 26 performance attributes evaluated.
Basel, Switzerland, May 31, 2023 – The Consumer Health Division of Bayer has launched a business unit focused on developing new Precision Health products across its range of everyday health categories. Bayer will prioritize developing products that enable people to take greater control of their own personal health through digital solutions that facilitate more informed choices based on personal insights and novel delivery mechanisms.
Novo Nordisk and Life Edit Therapeutics establish multi-target collaboration to discover and develop gene editing therapies for rare and cardiometabolic diseases
- Life Edit will receive an upfront cash payment and is eligible to receive milestone payments of 250-335 million US dollars for each of seven development programmes, as well as tiered royalties on global net sales.
- Life Edit has the option to a global profit share on one programme.
- Novo Nordisk will make an equity investment in ElevateBio, Life Edit’s parent company, as part of ElevateBio’s 401 million US dollars Series D financing.
Bagsværd, Denmark and Durham, NC, US, 24 May 2023 – Novo Nordisk and Life Edit Therapeutics, Inc., an ElevateBio company focused on next-generation gene editing technologies and therapeutics, today announced a research and development collaboration to discover and develop gene editing therapies against a select set of therapeutic targets.
Touchlight completes expansion, creating one of the world’s largest DNA manufacturing facilities in London, UK
- Facility will have capacity that exceeds today’s global plasmid DNA demand and can enable commercialisation of genetic medicines.
- Transformation of Grade II-listed Victorian waterworks on the River Thames in Hampton, London.
- Supplying many of the top biopharmaceutical companies in the world to dramatically enhance their ability to develop genetic medicines.
- Expansion follows recent acceptance of a Drug Master File and first investigational new drug application using doggybone DNA.
Hampton, UK, 24 May 2023 – Touchlight, a company pioneering enzymatic DNA production, a critical material in many new genetic medicine treatments, has completed the redevelopment and expansion of its UK manufacturing facility, housed in a repurposed Victorian waterworks on the banks of the River Thames.